CRISPR, base editing, prime editing, and epigenetic editing expand what medicine can rewrite, regulate, or silence.
Page status
- Needs delivery-system comparison table
- Needs current approved-product examples
Key takeaways
- The editing enzyme is only half the product; delivery determines where it can work.
- Ex vivo editing is easier to control than in vivo editing, but less convenient.
- Future aging applications will depend on targets with clear risk-benefit math.
Platform map
Nuclease editing cuts DNA. Base editing changes individual letters without a double-strand break. Prime editing can write more flexible edits. Epigenetic editing can tune gene expression without altering the underlying sequence.
These platforms are not interchangeable. Each has a different error profile, payload size, delivery constraint, and reversibility model.
Human deployment
Ex vivo workflows edit cells outside the body and return them after quality control. In vivo workflows deliver editors directly into tissues, which can be more scalable but harder to recall.
For future human enhancement, the barrier is not merely technical capability. Durable edits for low-risk conditions require extremely high confidence because harms can be permanent.
Watchlist
- Lipid nanoparticles
- AAV capacity
- Off-target assays
- Epigenetic reversibility
References
- FDA CRISPR therapy approval. U.S. FDA CASGEVY approval materials. Regulatory source for approved ex vivo CRISPR therapy indications.
- Exa-cel clinical evidence. Frangoul et al., New England Journal of Medicine, 2024. Clinical outcomes source for exagamglogene autotemcel in severe sickle cell disease.
What links here
- Cellular ReprogrammingPartial reprogramming aims to restore youthful cell function without erasing identity or triggering uncontrolled growth.
- Personalized RNA MedicineProgrammable RNA platforms can compress the path from molecular insight to tailored therapy, especially for rare or rapidly changing targets.
- Regenerative Organ PlatformsOrganoids, bioprinting, xenotransplantation, and perfusion systems are converging on the bottleneck of organ replacement.
- Synthetic BiologyEngineered cells and biological circuits could sense disease, manufacture therapies, and adapt inside the body.